Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria

Summary

The aim of this study is to test the hypothesis that the effects on albuminuria of combination treatment with the endothelin receptor antagonist zibotentan and SGLT2i dapagliflozin are complimentary and additive while the fluid retaining effects of zibotentan can be mitigated by dapagliflozin.

Timeline

Start

2022-10-06

Primary completion

2025-03-05

Completion

2025-03-05

Publications

• Hu S, Lee K, He JC, Fan Y. Current Landscape and Emerging Therapeutic Targets in Diabetic Kidney Disease. Clin J Am Soc Nephrol. 2026 Mar 10. doi: 10.2215/CJN.0000001053. Online ahead of print.

Drugs

Indications